Immunotherapy is the Hope of Advanced Tumor (Ringelhan et al., 2018), Phase I clinical trials showed that response rates to CTLA4 and PD-L1 Immunological checkpoint inhibitors were 17.6% and 20% (El-Khoueiry et al., 2017; Sangro et al., 2013). This evidence concerns the gene CTLA4 and neoplasm.